PCRX Earnings Date: Nov 5, 2026 (Estimated) — Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is PCRX's next earnings date?
Pacira BioSciences, Inc. (PCRX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.73 on revenue of $182.9M.
How did PCRX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Pacira BioSciences, Inc. posted EPS of $0.73 versus the $0.57 estimate, a beat of 28.1%. Revenue was $192.4M against a $190.9M estimate. The stock's 1-day post-earnings move was -10.0%.
How much does PCRX stock move after earnings?
PCRX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.2% (up or down) in the day after earnings.
About Pacira BioSciences, Inc.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.57 | 0.73 | +28.07% | $192.4M | ✅ Beat | -9.96% | -11.73% | -3.77% |
| 2026-04-30 | Q1 2026 | 0.52 | 0.60 | +15.38% | $177.4M | ✅ Beat | -4.12% | -7.26% | -9.93% |
| 2026-02-26 | Q4 2025 | 0.78 | 0.57 | -26.92% | $196.9M | ❌ Miss | -3.01% | +1.20% | +1.28% |
| 2025-11-06 | Q3 2025 | 0.56 | 0.70 | +25.00% | $179.5M | ✅ Beat | +4.50% | +11.94% | +15.73% |
| 2025-08-05 | Q2 2025 | 0.62 | 0.74 | +19.35% | $181.1M | ✅ Beat | -0.62% | +10.07% | +18.59% |
| 2025-02-27 | Q4 2024 | 0.83 | 0.91 | +9.64% | $187.3M | ✅ Beat | -5.24% | -5.99% | -1.85% |
| 2024-11-06 | Q3 2024 | 0.70 | 0.79 | +12.86% | $168.6M | ✅ Beat | +0.17% | -6.90% | +9.05% |
| 2024-07-30 | Q2 2024 | 0.70 | 0.89 | +27.14% | $178.0M | ✅ Beat | +5.68% | +10.59% | -23.75% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $374.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 50.9% | $190.5M | +5.6% | $187.3M | $167.6M | $180.3M | $178.0M |
| EXPAREL | 39.5% | $147.8M | +3.4% | $147.7M | $136.5M | $142.9M | $139.9M |
| ZILRETTA | 8.7% | $32.6M | +4.2% | $33.1M | $23.3M | $31.3M | $29.0M |
| Bupivacaine Liposome Injectable Suspension | 0.9% | $3.2M | +533.1% | — | $2.6M | $508K | $2.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.